RETNA GENE

Brand Owner (click to sort) Address Description
RETNAGENE SEQUENOM, INC. 3595 John Hopkins Court San Diego CA 92121 RETNA GENE;Scientific research in the field of age-related macular degeneration; laboratory research in the field of age-related macular degeneration; clinical research in the field of age-related macular degeneration science and medicine; medical research in the field of age-related macular degeneration; technological research in the field of age-related macular degeneration; scientific analysis in the field of age-related macular degeneration; laboratory scientific analysis in the field of age-related macular degeneration; clinical scientific analysis in the field of age-related macular degeneration; technological services, namely, scientific analysis in the field of age-related macular degeneration; genetic testing for scientific research purposes; genetic testing services in the field of age-related macular degeneration for scientific research purposes;
RETNAGENE SEQUENOM, INC. 3595 John Hopkins Court San Diego CA 92121 RETNA GENE;Medical services; genetic testing for medical purposes; medical diagnostic testing, and reporting services in the field of age-related macular degeneration; medical analysis in the field of age-related macular degeneration, namely, performing diagnosis of age-related macular degeneration and providing diagnostic and treatment information to others;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention comprises a method for producing mammalian therapeutics free from prion contamination and cells for use in such methods. Such therapeutics are produced in somatic cells having a genome with an artificially altered PrP gene. The PrP gene in these cells may be ablated, or replaced by an exogenous inducible form of the PrP gene. The endogenous gene in the host cells may be disrupted, or disrupted and replaced by an exogenous PrP gene.